In the last trading session, 1.03 million Cardiff Oncology Inc (NASDAQ:CRDF) shares changed hands as the company’s beta touched 1.80. With the company’s per share price at $3.47 changed hands at -$0.14 or -3.88% during last session, the market valuation stood at $230.82M. CRDF’s last price was a discount, traded about -85.01% off its 52-week high of $6.42. The share price had its 52-week low at $1.44, which suggests the last value was 58.5% up since then. When we look at Cardiff Oncology Inc’s average trading volume, we note the 10-day average is 1.23 million shares, with the 3-month average coming to 2.07 million.
Analysts gave the Cardiff Oncology Inc (CRDF) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CRDF as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight.
Cardiff Oncology Inc (NASDAQ:CRDF) trade information
Instantly CRDF was in red as seen at the end of in last trading. With action -26.17%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -20.05%, with the 5-day performance at -26.17% in the red. However, in the 30-day time frame, Cardiff Oncology Inc (NASDAQ:CRDF) is -8.20% down. Looking at the short shares, we see there were 9.95 million shares sold at short interest cover period of 2.92 days.
Cardiff Oncology Inc (CRDF) estimates and forecasts
Data shows that the Cardiff Oncology Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 38.25% over the past 6 months, a -6.45% in annual growth rate that is considerably lower than the industry average of 16.40%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 35.42%. The 2025 estimates are for Cardiff Oncology Inc earnings to decrease by -6.21%.
CRDF Dividends
Cardiff Oncology Inc is expected to release its next quarterly earnings report in February.
Cardiff Oncology Inc (NASDAQ:CRDF)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 5.62% of Cardiff Oncology Inc shares while 27.67% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 29.32%. There are 27.67% institutions holding the Cardiff Oncology Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 5.883% of the shares, roughly 2.63 million CRDF shares worth $5.84 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 4.7816% or 2.14 million shares worth $4.74 million as of 2024-06-30.
